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A new series of fluorinated 5-HT2C agonists were designed and synthesized on the basis of our previous
work on 2-phenylcyclopropylmethylamines as a potential approach for the treatment of central nervous
system disorders. Key fluorinated cyclopropane moieties were constructed through transition metal
catalyzed [2 þ 1]-cycloaddition of aromatic vinyl fluorides, and the absolute stereochemistry of the
representative compound (e)-21a was established. Functional activity measuring calcium flux at 5-HT2
receptors reveals high potency for compounds (þ)-21a-d. In particular, (þ)-21b had no detectable 5-HT2B
agonism and displayed reasonable selectivity against 5-HT2A. Molecular docking studies were further
performed to explain the compounds’ possible binding poses to the 5-HT2C receptor.1. Introduction
The 5-HT2-family of serotonin receptors are members of the G
protein-coupled receptor (GPCR) superfamily and consist of three
subtypes including 5-HT2C, 5-HT2B, and 5-HT2A, which share high
sequence homology [1]. The 5-HT2C receptor represents a prom-
ising drug target for obesity and central nervous system disorders,
such as schizophrenia and drug addiction [1e4]. Subtype selectivitymetabolism; excretion, and
ine; RIT, ritanserin; ERG,
ng).
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es.is essential for the development of potential 5-HT2C-targeted
therapeutics [5], as drugs with 5-HT2B agonism may induce
potentially life-threatening valvular hypertrophy [6,7], while 5-
HT2A agonists are hallucinogenic [8]. However, it is currently a
major challenge to develop agonists that are highly selective for 5-
HT2C over 5-HT2B and 5-HT2A due to these subtypes’ significant
homology at structural, genetic, and functional levels. Indeed, the
lack of truly selective ligands that are able to fully discriminate
among these receptor subtypes, especially between 5-HT2C and 5-
HT2B, has hampered the development of therapies based on these
compounds. For example, the withdrawal of fenfluramine and
pergolide as well as the restriction of sales of cabergoline are
related to their off-target agonist activity at the 5-HT2B receptor [7].
Furthermore, concern about the anti-obesity drug lorcaserin has
been raised because of its moderate 5-HT2B agonism, which may
induce lethal cardiac valvulopathy and pulmonary hypertension
[9,10]. Therefore, high selectivity for 5-HT2C over 5-HT2B has
emerged as paramount to develop 5-HT2C agonists as a new gen-
eration of therapeutic drugs [1].
Fluorination of bioactive molecules as a drug design strategy
has achieved remarkable success as evidenced by a number of
marketed drugs, mainly because of the strong electron-
withdrawing effects of the fluorine atom and the metabolic sta-
bility of the CeF bond [11e13]. In our systematic structural
optimization of 2-phenylcyclopropylmethylamines (2-PCPMAs),
the introduction of a halogen, especially fluorine, onto the phenyl
ring was demonstrated as a robust strategy to develop potent and
selective 5-HT2C agonists with improved drug-like properties. For
the first generation of 2-PCPMAs, introducing a fluorine substit-
uent at the 3-position of the phenyl ring (compound 3) generated
one of the most selective 5-HT2C agonists reported to date [14].
Subsequent structure-activity relationship (SAR) studies indi-
cated that an additional 2-alkoxy substituent represents a
beneficial functional group for maintaining reasonable potency
and selectivity as illustrated in compounds 7 and 8 [15]. Intro-
duction of a second halogen substituent resulted in the drug
candidate 9, which displayed exquisite 5-HT2C potency and
selectivity over 5-HT2A and 5-HT2B, excellent ADMET profiles, and
in vivo antipsychotic drug-like effects [16] (Fig. 1). Further N-
alkylation of the 2-(5-fluoro-2-alkoxyphenyl)cyclopropylmethyl-
amines led to the identification of the potent N-benzyl com-
pound 11 with full selectivity over 5-HT2B, and of the N-methyl
compound 10, which is the first fully Gq-biased 5-HT2C agonist
reported to date [17].
Based on the promising properties of 2-PCPMA derivatives
fluorinated in the phenyl ring reported in our prior work, we
further explored the incorporation of fluorine atom(s) into the
cyclopropane ring, which could: (1) change the compounds’
conformation and thereby possibly lead to higher potency and
selectivity; (2) increase lipophilicity for optimal brain penetration;
and (3) block potential sites of oxidative metabolism, such as the
benzylic position (Fig. 1). Accordingly, a series of fluorinated
cyclopropylmethylamine derivatives were designed, synthesized,
and evaluated for their activities at 5-HT2 receptors. Furthermore,
modelling studies were performed to understand their possible
binding poses at the 5-HT2C receptor.Fig. 1. Selected previously synthesized 5-HT2C agonists 1e11 based on the 2-phenylcyclop2. Results and discussion
2.1. Structure-activity relationship studies
Based on our previous findings that the second-generation 2-
PCPMAs possessing 2-alkoxy and 5-fluoro substituents exhibited
the best 5-HT2C potency and selectivity over 5-HT2A and 5-HT2B
receptors [15], an analog of the lead compound, 2-(5-fluoro-2-
methoxyphenyl)cyclopropylmethylamine (6, cLogP¼ 1.59,
LogBB¼0.04) that is fluorinated at the benzylic position, and
which can be readily modified to form different 2-alkoxy de-
rivatives, was synthesized first. Unfortunately, the resulting com-
pound (±)-12 showed only weak activity at 5-HT2C
(EC50¼ 598 nM). For our third-generation 2-PCPMAs with N-sub-
stituents, the introduction of an N-(2-methoxybenzyl) group led to
compounds with high 5-HT2C selectivity over 5-HT2B while main-
taining good potency at 5-HT2C [17]. However, the N-(2-
methoxybenzyl) analog (±)-13 of compound (±)-12 exhibited
only slightly improved activity at 5-HT2C (EC50¼ 230 nM,
Emax¼ 103%) together with poor selectivity against 5-HT2B and 5-
HT2A. Therefore, we concluded that the fluorinated cyclopropane
moiety and the 2-alkoxy group could not be accommodated
simultaneously, in line with our observation from prior structure-
activity relationship studies that suggested strict steric limitations
applying to 2-PCPMAs [14e16].
Therefore, we further designed fluorinated cyclopropane de-
rivatives based on the first-generation 2-PCPMAs, which were
considered to have less steric hindrance. According to the previous
SAR studies on the first-generation 2-PCPMAs (Fig. 1), substitutions
at the 3-position of the benzene ring with F (compound 3), Me
(compound 2), Cl (compound 4), and even Br and CF3 groups were
well tolerated without significant loss of activity at 5-HT2C despite a
gradual increase of the substituent size in this series. Moreover,
mono- and disubstituted ligands bearing Br and Cl at the 2-position
displayed higher potency than the corresponding analogs
substituted with F, Me, or CF3 groups, while the replacement of the
fluorine atom at the 4-position with other substituents led to
dramatically reduced 5-HT2C potency and selectivity [14]. On the
basis of these previous findings, the fluorinated cyclopropane de-
rivatives 21a-e of the potent and selective first-generation 5-HT2C
agonists 2e5 were investigated. The biological results areropylmethylamine scaffold, and new fluorinated cyclopropylmethylamine derivatives.
summarized in Table 1. Compared to the parent (2-
phenylcyclopropyl)methylamine ((þ)-1, EC50¼ 5.2 nM,
Emax¼ 108% at 5-HT2C, selectivity (2B/2C)¼ 7) [14], the fluorinated
cyclopropane derivative (þ)-21a showed comparable 5-HT2C ac-
tivity (EC50¼ 4.7 nM, Emax¼ 98%) and selectivity (2-fold) over 5-
HT2B. Substitution with a methyl group at the 3-position of the
phenyl ring of (þ)-21a led to identification of a potent 5-HT2C
agonist ((þ)-21b, EC50¼ 8.0 nM, Emax¼ 96%) with no detectable
agonism at 5-HT2B and about 20-fold selectivity against 5-HT2A
(EC50¼162 nM, Emax¼ 71%), while intriguingly the corresponding
parent (2-(3-methylphenyl)cyclopropyl)methaylamine ((±)-2,
EC50¼ 4.8 nM, Emax¼ 95% at 5-HT2C, selectivity (2B/2C)¼ 14) [14]
also had the best selectivity for 5-HT2C over 5-HT2B among the first-
generation 2-PCPMAs. The 3-fluoro and 3-chloro analogs ((þ)-21c
and (þ)-21d, respectively) displayed high potency (EC50< 15 nM) at
5-HT2C but poor selectivity against 5-HT2B and 5-HT2A receptors. In
contrast, the introduction of a bromo substituent into the 2-
position of the phenyl ring (compound (þ)-21e) resulted in
decreased potency (EC50¼ 312 nM, Emax¼ 71%) at 5-HT2C, although
the ligand showed no activity at 5-HT2B. N-Methylation and N-
benzylation of (þ)-21a, which was shown to be a successful opti-
mization strategy in the third-generation N-substituted PCPMAs
[17], caused loss of potency (EC50> 250 nM) at 5-HT2C as found in
compounds (þ)-22 and (þ)-23. Furthermore, the gem-difluorinated
cyclopropane derivative 24 was almost inactive (EC50> 4 mM),
which possibly resulted from the bulkier difluorinated cyclopro-
pane moiety.
Compound (þ)-21b has thus been identified as the best ligand in
the series with excellent selectivity for the 5-HT2C receptor againstTable 1
Functional activity and selectivity of fluorinated cyclopropylmethylamine derivatives 12e
Compd. X R3 R2 cLogP LogBB 5-HT2C
pEC50 (EC50, nM)
serotonin - 9.72± 0.03 (0.19)
lorcaserin - 8.32± 0.03 (4.77)
(±)-12 F OMe H 1.52 0.26 6.22± 0.07 (598)
(±)-13 F OMe 3.40 1.02 6.64± 0.05 (229)
(þ)-21a H H H 1.71 0.29 8.33± 0.05 (4.7)
(e)-21a 5.39± 0.05 (4106)
(þ)-21b Me H H 1.92 0.38 8.10± 0.61 (8.0)
(e)-21b 5.28± 0.15 (5245)
(þ)-21c F H H 1.71 0.29 8.56± 0.69 (3.0)
(e)-21c NA
(þ)-21d Cl H H 2.24 0.42 7.91± 0.82 (12)
(e)-21d 5.97± 0.41 (1064)
(þ)-21e H Br H 2.29 0.51 6.51± 0.30 (312)
(e)-21e NA
(þ)-22 H H Me 2.07 0.46 6.54± 0.14 (291)
(þ)-23 H H 3.63 1.10 6.10± 0.04 (789)
(±)-24 - 1.60 0.27 5.35± 0.11 (4426)
a All new compounds were tested as HCl salts. Pharmacological data were acquired w
using a fluorescence imaging plate reader (FLIPR) assay. All data are expressed as avera
performed in triplicate. “NA” indicates no activity up to 10 mM “” indicates structures of
free bases using the ACD Percepta program.5-HT2B (no agonism at 10 mM) and a reasonable selectivity against
5-HT2A. Moreover, the introduction of a fluorine atom into the
cyclopropane ring is beneficial for improving cLogP and logBB (for
example, 21b: cLogP¼ 1.92, logBB¼ 0.38 vs 2: cLogP¼ 1.95,
LogBB¼ 0.08), which might contribute to a better brain penetrance
of the compound for the treatment of central nervous system (CNS)
diseases.2.2. Chemistry
As shown in Scheme 1, the monofluorinated cyclopropane de-
rivative 12was synthesized starting from commercially available 5-
fluoro-2-methoxybenzaldehyde (12a). Wittig reaction of benzal-
dehyde 12a with methyltriphenylphosphonium bromide afforded
the olefin 12b in a high yield. Bromofluorination of 12b with NBS/
Et3N·3HF followed by elimination of HBr provided the vinyl fluoride
12d. Cyclopropanation of 12d with ethyl diazoacetate in the pres-
ence of Cu(acac)2 as catalyst generated the monofluorinated
cyclopropanecarboxylate 12e as an approximate 3:2 racemic
mixture of trans- and cis-isomers. The trans-isomer 12e was ob-
tained by chromatographic separation. Its reduction to the corre-
sponding aldehyde with diisobutylaluminium hydride (DIBAL-H)
proceeded in a good yield, but this compound was found to readily
decompose under weakly acidic conditions such as in presence of
deuterated chloroform. This problem was solved by the direct
reduction of 12ewith LiAlH4 to alcohol 12f, which was transformed
to azide 12g via a Mitsunobu azidation with PPh3/DEAD/DPPA.
Staudinger reduction of 12g followed by Boc-protection of the
primary amine in one pot produced the N-Boc amide 12h, which13, 21a-e, and 22e24 at 5-HT2 receptors in the calcium flux assaya
5-HT2B 5-HT2A
Emax (%) pEC50 (EC50, nM) Emax (%) pEC50 (EC50, nM) Emax (%)
100± 0.8 9.07± 0.03 (0.86) 100± 0.8 9.56± 0.02 (0.27) 100± 0.7
101± 1.2 7.10± 0.06 (80) 92± 2.6 7.49± 0.04 (33) 92± 1.3
90± 3.0 6.94± 0.07 (116) 79± 2.2 6.45± 0.03 (352) 86± 1.2
103± 2.4 6.55± 0.04 (285) 61± 1.2 7.51± 0.02 (31) 92± 0.6
98± 1.5 8.00± 0.08 (10) 104± 3.0 8.01± 0.05 (10) 106± 1.7
87± 3.0 6.04± 0.11 (903) 77± 4.5 5.74± 0.04 (1829) 47± 1.1
96±1.5 NA NA 6.79± 0.87 (162) 71± 1.1
97± 0.8 NA NA NA NA
107± 1.9 8.64± 0.77 (2.0) 106± 2.0 8.57± 0.53 (3.0) 83± 1.7
NA NA NA NA NA
110± 1.6 7.66± 0.20 (22) 91± 1.8 7.64± 0.56 (23) 102± 1.3
92± 1.3 NA NA NA NA
71± 1.2 NA NA 6.91± 0.19 (122) 38± 1.3
NA NA NA NA NA
96± 1.1 6.25± 0.02 (565) 42± 1.3 6.81± 0.80 (156) 40± 1.1
85± 1.9 6.44± 0.20 (363) 27± 2.4 6.50± 0.04 (320) 83± 1.4
82± 6.4 5.63± 0.16 (2347) 62± 6.3 5.43± 0.12 (3679) 43± 3.6
ith recombinant, stably expressed human 5-HT2 receptors in the HEK-293 cell line,
ge and standard error of the mean and represent three independent experiments
5-HT and lorcaserin are not shown. cLogP and LogBB values were calculated for the
Scheme 1. Synthesis of target compounds 12-13aaReagents and conditions: (a) Ph3(CH3)PþBr, NaH, THF; (b) Et3Ne3HF, NBS, CH2Cl2; (c) DBU, CH2Cl2, reflux; (d) N2CHCOOEt,
Cu(acac)2, 1,2-dichloroethane, 60 C; (e) LiAlH4, THF; (f) DPPA, DEAD, Ph3P, THF, 0 C ~ rt; (g) Ph3P, H2O/THF; then Boc2O; (h) 2M HCl/Et2O; (i) 2-methoxybenzaldehyde, NaBH4,
MeOH.was easily purified by column chromatography. Deprotection of
12h with HCl solution (2.0M in diethyl ether) afforded the primary
amine derivative 12 as its HCl salt. The N-benzylated derivate 13
was prepared by reductive alkylation of 12 with 2-
methoxybenzaldehyde.
As shown in Scheme 2, the styrenes 14a-ewere converted to the
trans-isomers of monofluorinated cyclopropanecarboxylates 17a-e
according to the same method as described in Scheme 1. Subse-
quently, compounds 17a-e were subjected to a five-step sequence
following similar procedures as reported previously by us [16].
Reduction of 17a-e with LiAlH4 afforded alcohols 18a-e in good
yields, which were then converted into phthalimides 18a-e via
Mitsunobu reactions with phthalimide. Deprotection of the imides
with hydrazine hydrate and subsequent Boc-protection produced
intermediates 20a-e. Separation of racemic 20a-e by chiral pre-
parative HPLC followed by deprotection of the Boc group under
acidic conditions (2M HCl/Et2O) gave optically pure enantiomers
(þ)-21a-e and (e)-21a-e as HCl salts. The N-methylamine (þ)-22
was prepared by introduction of the N-methyl group into the in-
termediate (e)-20a with sodium hydride and iodomethane fol-
lowed by removal of the Boc group under acidic conditions, while
the N-benzylamine (þ)-23 was directly synthesized from the
enantiomer (þ)-21a through reductive amination with 2-
methoxybenzaldehyde.
The synthesis of the gem-difluorinated cyclopropane 24 was
accomplished starting from the precursor 24b (Scheme 3), ob-
tained through difluorocyclopropanation of cinnamyl acetate
(24a) with an excesses of sodium chlorodifluoroacetate in
diglyme under reflux [18]. Saponified afforded the alcohol 24c in
quantitative yield, which was then subjected to similar synthetic
procedures as described above to provide the gem-difluor-
ocyclopropane 24.
Unless otherwise noted, the fluorinated cyclopropylmethyl-
amine derivatives were tested as racemic mixtures. The absolute
stereochemistry of compound (e)-21a was established by com-
parison of the optical rotation of its N-Boc precursor (þ)-20a ob-
tained from chiral HPLC separation to that of a sample synthesized
asymmetrically. The enantioselective synthesis of the key inter-
mediate trans-(e)-(1S,2S)-17a for preparation of (þ)-(1S,2S)-20awas achieved by asymmetric cyclopropanation of a-fluorostyrene
(16a) in the presence of an enantiopure copper catalytic system
consisting of the chiral bis(oxazoline) ligand 25 and copper(I) tri-
flate [19,20] (Scheme 4). Following the same synthetic route as
shown in Scheme 2, trans-(e)-(1S,2S)-17a was transformed into
(þ)-(1S,2S)-20a, which was identical to the enantiomer (þ)-20a
obtained from chiral HPLC separation in terms of optical rotation
and spectral data. Based on this result, the absolute configuration of
(e)-21a obtained by removal of the N-Boc group from (þ)-20awas
assigned as (1S,2S) and that of the other enantiomer, (þ)-20a, as
(1R,2R). Furthermore, our finding that the (þ)-enantiomers of all
new fluorinated cyclopropylmethylamine derivatives 21a-e are
more potent than their (e)-enantiomers is in agreement with that
previously observed for the 2-phenylcyclopropylmethylamine
scaffold [14]. Taken together, the absolute configuration of com-
pounds (þ)-21a-e is generally assumed as (1R,2R) and that of
(e)-21a-e as (1S,2S).
2.3. Molecular docking studies
To clarify the potential binding poses of the new fluorinated
cyclopropane compounds compared to those of our previous
compounds, we conducted molecular docking studies using the
recently published crystal structures of the 5-HT2C receptor [21].
The transition from 5-HT2C inactive to active states is thought to
be triggered by helix movements accompanied by rotamer
switches in the conserved P3265.50-I1423.40-F3206.44 (PeIeF) motif
and a shift of the W3246.48 in helix VI, a hallmark of representative
active-state-like structures at biogenic amine and other GPCRs
[22,23]. The recently reported inactive and active structures of the
5-HT2C receptor in complex with ritanserin (RIT) and ergotamine
(ERG), respectively, demonstrate that, by comparing the confor-
mational changes between inverse agonist- and agonist-bound 5-
HT2C, hydrogen bonds between the highly conserved D1343.32
and Y3587.43 residues are in place in both structures, while one of
RIT's 4-fluorophenyl rings forms a strong, tight interaction with
W3246.48 and I1423.40, as well as F3206.44 side chains, thus appar-
ently preventing the conformational changes in these key activa-
tion microswitch structures [21].
Scheme 2. Synthesis of Target Compounds 21a-e, 22, and 23aaReagents and conditions: (a) Et3Ne3HF, NBS, CH2Cl2; (b) DBU, CH2Cl2, reflux; (c) N2CHCOOEt, Cu(acac)2, CH2Cl2, 40 C;
(d) LiAlH4, THF; (e) phthalimide, PPh3, DEAD, THF, 0 C ~ rt; (f) 1. N2H4eH2O, EtOH, reflux; 2. Boc2O, Et3N, DCM; (g) chiral preparative HPLC separation; (h) 2M HCl/Et2O; (i) NaH, MeI,
THF; (j) 2-methoxybenzaldehyde, NaBH4, MeOH.
Scheme 3. Synthesis of target compounds 24aaReagents and conditions: (a) ClCF2COONa, diglyme, 162 C; (b) 2N NaOH, MeOH; (c) phthalimide, PPh3, DEAD, THF, 0 C ~ rt; (d) 1.
N2H4eH2O, EtOH, reflux; 2. Boc2O, Et3N, DCM; (e) 2M HCl/Et2O.On the basis of the available 5-HT2C-active crystal structure (PDB
code: 6BQG, Fig. 2A), a docking simulation was carried out on the
potent and highly selective agonist 8 and its corresponding fluori-
nated cyclopropane derivative 21c to interpret their possiblebinding modes (Fig. 2B and C). Expectedly, both ligands engage in a
strong salt bridge with D1343.32, which is critical for charged ami-
nergic ligand recognition. Furthermore, the salt bridge is enhanced
by an interaction between D1343.32 and the fluorine-substituted
Scheme 4. Asymmetric synthesis of intermediate (þ)-20a.
Fig. 2. Docking simulations of 8 and 21c with 5-HT2C-active. (A) Empirical conformation of ERG (orange) in 5-HT2C-active (PDB: 6BQG); (B) docking pose of 8 (green) in the binding
site of 5-HT2C-active; (C) docking pose of 21c (magenta) in the binding site of 5-HT2C-active; (D) superimposed structures of 8 (green) and 21c (magenta) in the binding site of 5-HT2C-
active. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)alkoxy tail in the case of 8, while an additional interaction between
the amino group and S1383.36 is observed in the complex of 21c.
Both the alkyl side chain in 8 and the cyclopropyl ring in 21c also
participate in additional p-alkyl interactions with W3246.48 that
may reinforce interactions with helix VI toward an active confor-
mation. In addition, the fluorophenyl rings in both compounds
engage in an interaction with G2185.42 and an edge-to-face p-p
stacking with F3286.52, suggesting that interhelical interactions areinvolved to stabilize helices III, V, and VI in 5-HT2C-active. The
superimposed structures of 8 and 21c in Fig. 2D further demon-
strate that both fluorophenyl rings occupy relatively similar bind-
ing poses (Fig. 2D). However, the cyclopropane moiety of 8 forms a
salt bridge from the top of D1343.32, while the fluorinated cyclo-
propane moiety of 21c binds to D1343.32 from the downside of the
residue and locates at a similar position as the 2-fluoroethoxy
group of 8.
3. Conclusions
Based on the expected favorable drug-like properties imparted
by fluorine substituent(s) on the phenyl ring of the 2-PCPMA
scaffold, new fluorinated cyclopropylmethylamine derivatives
were designed and synthesized by construction of the cyclopro-
pane ring via transition metal catalyzed [2 þ 1]-cycloaddition of a
diazo compound to an aromatic vinyl fluoride. The absolute ste-
reochemistry of the enantiomers (þ)-21a-e and (e)-21a-e was
indirectly determined by comparison of the N-Boc protected pre-
cursor of the representative compound (e)-21a obtained by chiral
HPLC separation to a sample synthesized asymmetrically by a well-
proven methodology. Further pharmacological profiling of these
compounds led to identification of a potent and highly selective 5-
HT2C agonist, (þ)-21b, without 5-HT2B agonism. Molecular docking
studies using recently disclosed crystal structures of the 5-HT2C
receptor indicate that the new fluorinated cyclopropane com-
pounds such as 21c have similar interaction patterns with 5-HT2C
compared to the best ligand 8 reported previously by us. Intro-
duction of the fluorine atom at the benzylic position of 2-PCPMA
may contribute to improved drug-like properties with regard to
metabolic stability and brain penetration crucial for CNS drugs.4. Experimental section
4.1. General
All chemicals and solvents were purchased from Sigma-Aldrich
or Fisher Scientific and were used as obtained without further
purification. Synthetic intermediates were purified on 230e400
mesh silica gel using a Teledyne CombiFlash Rf flash chromato-
graph. 1H, 13C, and 19F NMR spectra were recorded on Bruker DPX-
400 or AVANCE-400 spectrometers at 400MHz, 100MHz, and
376MHz, respectively. NMR chemical shifts are reported in d (ppm)
using residual solvent peaks as standards (CDCl3e7.26 (H), 77.16
(C); CD3ODe3.31 (H), 49.00 (C)). High resolution mass spectra
(HRMS) were acquired using an LCMS-IT-TOF (Shimadzu) mass
spectrometer in ESI mode. Preparative HPLC purification of syn-
thetic intermediates was performed on a Shimadzu LC-8A instru-
ment with an ACE 5AQ column (150 21.2mm, particle size 5 mm;
eluent: 8e100% MeOH (0.05% TFA)/H2O (0.05% TFA) gradient,
30min; flow rate: 17mL/min; UV detection at 220 and 254 nm).
The purity of all final compounds (greater than 95% in all cases) was
determined by analytical HPLC on an ACE 3AQ C18 column
(150 4.6mm, particle size 3 mm; eluent: MeOH (0.05% TFA)/H2O
(0.05% TFA) gradient, 25min; flow rate: 1.0mL/min).
The synthetic procedures and characterization data of all in-
termediates can be found in the Supporting Information.4.2. General Method A
Chiral Separation of N-Boc-amines 20a-e. The racemic N-Boc-
amines 20a-e were separated by preparative HPLC using a Regis-
Pack chiral column (25 cm 21.1mm, particle size 10 mM) and
2e10% ethanol in n-hexane as the eluent (flow rate¼ 18mL/min,
l¼ 220 and 254 nm; isocratic elution, stacked injections). The first-
and second-eluting peaks were collected and concentrated, and
separations were repeated when necessary to ensure obtention of
both enantiomers with optical purities >90% ee (determined by
analytical HPLC using a RegisPack (25 cm 4.6mm, particle size
10 mm) chiral column and ethanol/n-hexane as the eluent). Specific
rotations were recorded on a Rudolph Research Autopol IV auto-
matic polarimeter. Compounds (þ)-20a-ewere isolated as the first-
eluting peaks, and ()-20a-e as the second-eluting peaks.4.3. General Method B
Preparation of HCl Salts 12, (þ)/()-21a-e, 22, and 24. The N-
Boc-amines 12h, (þ)/()-20a-e, (þ)-22a, and 24ewere dissolved in
2M HCl (g) in diethyl ether (5 equiv.) and stirred at room temper-
ature for 24e48 h. The resulting white solids were filtered off,
washed with diethyl ether, and dried under vacuum to give the HCl
salts as white solids in high yields (75e90%).
4.4. [2-Fluoro-2-(5-fluoro-2-methoxyphenyl)cyclopropyl]
methanamine hydrochloride (12)
Obtained from the intermediate 12h employing GeneralMethod
B as a white solid. 1H NMR (CD3OD) d 7.24 (ddd, J¼ 8.6, 3.0, 1.9 Hz,
1H), 7.17 (tdd, J¼ 8.1, 3.1, 1.7 Hz, 1H), 7.08 (dd, J¼ 9.1, 4.3 Hz, 1H),
3.91 (s, 3H), 3.42 (ddd, J¼ 13.3, 6.3, 1.2 Hz, 1H), 3.22e3.14 (m, 1H),
1.66e1.56 (m, 1H), 1.52 (td, J¼ 10.2, 7.1 Hz, 1H), 1.35 (dt, J¼ 20.0,
7.0 Hz, 1H). 13C NMR (CD3OD) d 157.86 (d, J¼ 238.0 Hz), 156.15 (d,
J¼ 8.5 Hz), 126.64 (dd, J¼ 19.8, 7.3 Hz), 118.16 (dd, J¼ 22.7, 2.2 Hz),
118.02 (dd, J¼ 24.0, 4.2 Hz), 113.53 (d, J¼ 8.0 Hz), 79.24 (d,
J¼ 216.1 Hz), 56.58 (s), 40.16 (d, J¼ 9.3 Hz), 21.38 (d, J¼ 12.1 Hz),
16.28 (d, J¼ 13.4 Hz). 19F NMR (CD3OD) d 125.90 (s), 184.10 (s);




To a solution of the HCl salt 12 (50mg, 0.30mmol) and 2-
methoxybenzaldehyde (40mg, 0.30mmol) in methanol (5mL)
was added triethylamine (90mg, 0.90mmol). The reaction mixture
was stirred at rt for 6 h, and then NaBH4 (35mg, 0.90mmol) was
added in portions. The resulting mixture was further stirred for
30min, quenched by the addition of water and extractedwith DCM.
The organic layer was washed with brine, dried over Na2SO4, and
concentrated. The resulting residue was purified by silica gel
chromatography to give the free base as a colorless oil (72mg). The
above free basewas dissolved in 2MHCl in diethyl ether (3mL) and
stirred at room temperature for 2 h. The precipitate was collected
by filtration, washed with diethyl ether, and dried under vacuum to
obtain the desired salt as a white solid (76mg, 78%). 1H NMR
(CDCl3) d 12.19 (s, 2H), 7.50e7.36 (m, 2H), 7.18e7.00 (m, 3H), 6.95 (d,
J¼ 8.3 Hz, 1H), 6.91 (dd, J¼ 9.0, 4.1 Hz, 1H), 4.55 (d, J¼ 12.7 Hz, 1H),
4.02 (d, J¼ 11.9 Hz, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 3.83e3.70 (m, 1H),
2.77e2.62 (m, 1H), 2.04e1.84 (m, 1H), 1.46e1.36 (m, 1H), 1.24e1.12
(m, 1H); 19F NMR (CDCl3) d 123.00 (s), 184.03 (s). HRMS (ESI)




Obtained from the intermediate (-)-20a employing General
Method B as a white solid. 1H NMR (CD3OD) d 7.52e7.30 (m, 5H),
3.40e3.21 (m, 2H), 1.81e1.68 (m, 1H), 1.60e1.44 (m, 2H); 13C NMR
(CD3OD) d 139.36 (d, J¼ 20.8 Hz), 129.64 (s, 2C), 129.15 (s), 125.67
(d, J¼ 6.4 Hz, 2C), 82.24 (d, J¼ 217.7 Hz), 39.65 (d, J¼ 9.8 Hz), 23.68
(d, J¼ 11.2 Hz), 19.17 (d, J¼ 12.3 Hz); HRMS (ESI) calculated for




Obtained from the intermediate (þ)-20a employing General
Method B as a white solid. 1H NMR (CDCl3) d 7.53e7.30 (m, 5H),
3.40e3.20 (m, 2H), 1.81e1.68 (m, 1H), 1.60e1.44 (m, 2H); 13C NMR
(CD3OD) d 139.36 (d, J¼ 20.8 Hz), 129.64 (s, 2C), 129.15 (s), 125.67
(d, J¼ 6.4 Hz, 2C), 82.24 (d, J¼ 217.6 Hz), 39.65 (d, J¼ 9.8 Hz), 23.68
(d, J¼ 11.2 Hz), 19.17 (d, J¼ 12.3 Hz); HRMS (ESI) calculated for




Obtained from the intermediate (-)-20b employing General
Method B as awhite solid. 1H NMR (CD3OD) d 7.30 (t, J¼ 7.6 Hz, 1H),
7.24e7.13 (m, 3H), 3.37e3.30 (m, 1H), 3.24 (dd, J¼ 13.3, 8.2 Hz, 1H),
2.38 (s, 3H), 1.73e1.61 (m,1H), 1.60e1.41 (m, 2H); 13C NMR (CD3OD)
d 139.56 (s), 139.25 (d, J¼ 20.3 Hz), 129.87 (s), 129.53 (d,
J¼ 10.7 Hz), 126.28 (d, J¼ 6.4 Hz), 122.77 (d, J¼ 6.5 Hz), 82.22 (d,
J¼ 217.7 Hz), 39.68 (d, J¼ 9.9 Hz), 23.63 (d, J¼ 11.2 Hz), 21.43 (s),
19.02 (d, J¼ 12.5 Hz); 19F NMR (CD3OD) d 192.4 (s); HRMS (ESI)
calculated for C11H15FN ([MþH]þ): m/z 180.1183; found: 180.1176.
[a]D20 þ53.6 (c 0.5, MeOH).
4.9. (-)-[(1S,2S)-2-fluoro-2-(m-tolyl)cyclopropyl]methanamine
hydrochloride ((-)-21b)
Obtained from the intermediate (þ)-20b employing General
Method B as awhite solid. 1H NMR (CD3OD) d 7.30 (t, J¼ 7.6 Hz, 1H),
7.25e7.13 (m, 3H), 3.37e3.30 (m, 1H), 3.24 (dd, J¼ 13.3, 8.0 Hz, 1H),
2.38 (s, 3H), 1.73e1.62 (m,1H), 1.60e1.41 (m, 2H); 13C NMR (CD3OD)
d 139.56 (s), 139.25 (d, J¼ 20.3 Hz), 129.87 (s), 129.53 (d,
J¼ 10.7 Hz), 126.28 (d, J¼ 6.4 Hz), 122.77 (d, J¼ 6.5 Hz), 82.22 (d,
J¼ 217.6 Hz), 39.68 (d, J¼ 9.9 Hz), 23.63 (d, J¼ 11.2 Hz), 21.43 (s),
19.02 (d, J¼ 12.5 Hz); 19F NMR (CD3OD) d 192.4 (s); HRMS (ESI)
calculated for C11H15FN ([MþH]þ): m/z 180.1183; found: 180.1175.
[a]D20 -49.8 (c 0.1, MeOH).
4.10. (þ)-[(1R,2R)-2-fluoro-2-(3-fluorophenyl)cyclopropyl]
methanamine hydrochloride ((þ)-21c)
4.10.1. Obtained from the intermediate (-)-20c employing General
Method B as a white solid
1H NMR (CD3OD) d 7.48e7.39 (m, 1H), 7.19e7.13 (m, 2H),
7.13e7.05 (m, 1H), 3.39e3.34 (m, 1H), 3.23 (dd, J¼ 13.4, 8.1 Hz, 1H),
1.78e1.68 (m,1H), 1.65e1.48 (m, 2H); 13C NMR (CD3OD) d 164.40 (d,
J¼ 245.1 Hz), 142.39 (dd, J¼ 21.6, 7.5 Hz), 131.65 (d, J¼ 8.4 Hz),
120.89 (d, J¼ 4.3 Hz), 115.72 (d, J¼ 21.4 Hz), 112.45 (dd, J¼ 23.9,
7.8 Hz), 81.69 (d, J¼ 218.7 Hz), 39.50 (d, J¼ 9.9 Hz), 24.34 (d,
J¼ 11.0 Hz), 19.56 (d, J¼ 11.9 Hz); 19F NMR (CD3OD) d 114.77
(s),194.54 (s); HRMS (ESI) calculated for C10H12F2N ([MþH]þ):m/z
184.0932; found: 184.0948. [a]D20 þ40.8 (c 0.2, MeOH).
4.11. (-)-[(1S,2S)-2-fluoro-2-(3-fluorophenyl)cyclopropyl]
methanamine hydrochloride ((-)-21c)
Obtained from the intermediate (þ)-20c employing General
Method B as a white solid. 1H NMR (CD3OD) d 7.48e7.39 (m, 1H),
7.19e7.13 (m, 2H), 7.13e7.05 (m, 1H), 3.39e3.34 (m, 1H), 3.23 (dd,
J¼ 13.4, 8.0 Hz, 1H), 1.78e1.68 (m, 1H), 1.65e1.48 (m, 2H); 13C NMR
(CD3OD) d 164.40 (d, J¼ 245.2 Hz), 142.39 (dd, J¼ 21.6, 7.5 Hz),
131.65 (d, J¼ 8.4 Hz), 120.89 (d, J¼ 4.3 Hz), 115.72 (d, J¼ 21.4 Hz),
112.45 (dd, J¼ 23.9, 7.8 Hz), 81.69 (d, J¼ 218.7 Hz), 39.50 (d,
J¼ 9.9 Hz), 24.34 (d, J¼ 11.0 Hz), 19.56 (d, J¼ 11.9 Hz); 19F NMR
(CD3OD) d 114.77 (s), 194.54 (s); HRMS (ESI) calculated for
C10H12F2N ([MþH]þ): m/z 184.0932; found: 184.0935. [a]D20 -42.6 (c
0.1, MeOH).4.12. (þ)-[(1R,2R)-2-(3-chlorophenyl)-2-fluorocyclopropyl]
methanamine hydrochloride ((þ)-21d)
Obtained from the intermediate (-)-20d employing General
Method B as a white solid. 1H NMR (CD3OD) d 7.46e7.34 (m, 3H),
7.28 (d, J¼ 7.5 Hz, 1H), 3.39e3.33 (m, 1H), 3.24 (dd, J¼ 13.4, 8.1 Hz,
1H), 1.81e1.68 (m, 1H), 1.66e1.48 (m, 2H); 13C NMR (CD3OD)
d 141.84 (d, J¼ 21.3 Hz), 135.69 (s), 131.31 (s), 129.08 (d, J¼ 9.7 Hz),
125.64 (d, J¼ 7.6 Hz), 123.66 (d, J¼ 6.8 Hz), 81.66 (d, J¼ 218.5 Hz),
39.48 (d, J¼ 9.8 Hz), 24.19 (d, J¼ 10.9 Hz), 19.42 (d, J¼ 12.1 Hz); 19F
NMR (CD3OD) d 194.37 (s); HRMS (ESI) calculated for C10H12ClFN




Obtained from the intermediate (þ)-20d employing General
Method B as a white solid. 1H NMR (CD3OD) d 7.46e7.34 (m, 3H),
7.28 (d, J¼ 7.5 Hz, 1H), 3.39e3.33 (m, 1H), 3.24 (dd, J¼ 13.4, 8.0 Hz,
1H), 1.81e1.68 (m, 1H), 1.66e1.48 (m, 2H); 13C NMR (CD3OD)
d 141.84 (d, J¼ 21.3 Hz), 135.69 (s), 131.31 (s), 129.08 (d, J¼ 9.7 Hz),
125.64 (d, J¼ 7.6 Hz), 123.66 (d, J¼ 6.8 Hz), 81.66 (d, J¼ 218.5 Hz),
39.48 (d, J¼ 9.8 Hz), 24.19 (d, J¼ 10.9 Hz), 19.42 (d, J¼ 12.0 Hz); 19F
NMR (CD3OD) d 194.37 (s); HRMS (ESI) calculated for C10H12ClFN




4.14.1. Obtained from the intermediate (-)-20e employing General
Method B as a white solid
1H NMR (CD3OD) d 7.72 (d, J¼ 7.9 Hz, 1H), 7.60 (dt, J¼ 7.6, 1.9 Hz,
1H), 7.45 (t, J¼ 7.5 Hz, 1H), 7.38 (m, 1H), 3.52 (dd, J¼ 13.4, 6.2 Hz,
1H), 3.19 (ddd, J¼ 13.4, 8.7, 1.2 Hz, 1H), 1.72e1.61 (m, 1H), 1.60e1.45
(m, 2H); 13C NMR (CD3OD) d 136.51 (d, J¼ 19.0 Hz), 134.54 (s),
133.15 (d, J¼ 2.3 Hz), 132.76 (d, J¼ 2.4 Hz), 128.93 (s), 126.94 (s),
82.88 (d, J¼ 218.9 Hz), 39.94 (d, J¼ 8.4 Hz), 21.70 (d, J¼ 11.8 Hz),
17.40 (d, J¼ 13.3 Hz); 19F NMR (CD3OD) d 181.76 (s); HRMS (ESI)
calculated for C10H12BrFN ([MþH]þ): m/z 244.0132; found:
244.0105. [a]D20 þ80.3 (c 0.2, MeOH).
4.15. (-)-[(1R,2R)-2-(2-bromophenyl)-2-fluorocyclopropyl]
methanamine hydrochloride ((-)-21e)
Obtained from the intermediate (þ)-20e employing General
Method B as awhite solid. 1H NMR (CD3OD) d 7.72 (d, J¼ 8.0 Hz,1H),
7.60 (dt, J¼ 7.6, 1.9 Hz, 1H), 7.45 (t, J¼ 7.5 Hz, 1H), 7.38 (m, 1H), 3.52
(dd, J¼ 13.4, 6.2 Hz, 1H), 3.19 (ddd, J¼ 13.4, 8.7, 1.2 Hz, 1H),
1.72e1.62 (m,1H), 1.60e1.45 (m, 2H); 13C NMR (CD3OD) d 136.51 (d,
J¼ 19.0 Hz), 134.54 (s), 133.15 (d, J¼ 2.3 Hz), 132.76 (d, J¼ 2.4 Hz),
128.93 (s), 126.94 (s), 82.88 (d, J¼ 218.9 Hz), 39.94 (d, J¼ 8.4 Hz),
21.70 (d, J¼ 11.8 Hz), 17.40 (d, J¼ 13.3 Hz); 19F NMR (CD3OD)
d 181.76 (s); HRMS (ESI) calculated for C10H12BrFN ([MþH]þ): m/z
244.0132; found: 244.0110. [a]D20 -85.6 (c 0.1, MeOH).
4.16. (þ)-1-[(1R,2R)-2-fluoro-2-phenylcyclopropyl]-N-
methylmethanaminehydrochloride ((þ)-22)
To a solution of (-)-21a (23mg, 0.09mmol) in THF (12mL) was
added NaH (60% dispersion in mineral oil, 6mg, 0.13mmol). The
mixture was stirred at room temperature for 30min, and then
methyl iodide (20mg, 0.13mmol) was added. The reaction mixture
was stirred overnight at room temperature, quenched with water,
and extracted with EtOAc. The organic phase was washed with
brine, dried over anhydrous Na2SO4, and concentrated. The crude
product was purified by flash chromatography to give the inter-
mediate N-Boc-N-methylmethanamine 22a as a colorless oil
(20mg). Subsequent N-Boc deprotection afforded the desired HCl
salt according to General Method B as a white solid (12mg, 64%
yield). 1H NMR (CDCl3) d 9.40 (s, 2H), 7.42e7.35 (m, 2H), 7.35e7.29
(m, 3H), 3.64e3.44 (m, 1H), 3.27e3.09 (m, 1H), 2.73 (s, 3H),
2.00e1.81 (m, 1H), 1.58e1.40 (m, 2H); 13C NMR (CDCl3) d 137.48 (d,
J¼ 20.8 Hz), 128.83 (s, 2C), 128.32 (s), 124.54 (d, J¼ 6.7 Hz, 2C),
80.81 (d, J¼ 219.2 Hz), 47.24 (d, J¼ 8.6 Hz), 32.40 (s), 21.07 (d,
J¼ 10.9 Hz), 18.81 (d, J¼ 12.5 Hz); 19F NMR (CDCl3) d 188.7 (s);
HRMS (ESI) calculated for C11H15FN ([MþH]þ):m/z 180.1183; found:
180.1175. [a]D20 þ40.5 (c 0.1, MeOH).
4.17. (þ)-1-[(1R,2R)-2-fluoro-2-phenylcyclopropyl]-N-(2-
methoxybenzyl)methanamine hydrochloride ((þ)-23)
To a solution of the HCl salt (þ)-21a (50mg, 0.30mmol) and 2-
methoxybenzaldehyde (40mg, 0.30mmol) in methanol (5mL) was
added Et3N (90mg, 0.90mmol). The reactionmixturewas stirred at
rt for 6 h, and then NaBH4 (35mg, 0.90mmol) was added in por-
tions. The resulting mixture was further stirred for 30min,
quenched by the addition of water, and extracted with DCM. The
organic layer was washed with brine, dried over Na2SO4, and
concentrated. The resulting residue was purified by silica gel
chromatography to give the free base as a colorless oil (72mg). The
above free base was dissolved in 2MHCl in diethyl ether (3mL) and
stirred at room temperature for 2 h. The precipitate was collected
by filtration, washed with diethyl ether, and dried under vacuum to
obtain the desired salt as a white solid (76mg, 78%). 1H NMR
(CDCl3) d 9.98 (br s, 2H), 7.48 (dd, J¼ 7.4, 1.2 Hz, 1H), 7.39e7.35 (m,
2H), 7.32e7.28 (m, 4H), 6.92 (t, J¼ 7.4 Hz, 1H), 6.85 (d, J¼ 8.2 Hz,
1H), 4.18e4.06 (m, 2H), 3.82 (s, 3H), 3.35e3.28 (m, 1H), 3.06e3.01
(m, 1H), 1.97e1.93 (m, 1H), 1.46e1.28 (m, 2H); 13C NMR (CDCl3)
d 157.97 (s), 137.77 (d, J¼ 20.7 Hz), 132.14 (s), 131.22 (s), 128.67 (s,
2C), 128.15 (s), 124.65 (d, J¼ 6.6 Hz, 2C), 120.95 (s), 118.88 (s), 110.60
(s), 81.11 (d, J¼ 218.6 Hz), 55.54 (s), 45.55 (s), 44.77 (d, J¼ 8.7 Hz),
21.23 (d, J¼ 10.8 Hz), 19.13 (d, J¼ 12.5 Hz); HRMS (ESI) calculated
for C18H21FNO ([MþH]þ): m/z 286.1602; found: 286.1589. [a]D20
þ53.6 (c 0.1, MeOH).
4.18. (2,2-Difluoro-3-phenylcyclopropyl)methanamine
hydrochloride (24)
Obtained from the intermediate 24e employing General Method
B as a white solid. 1H NMR (CD3OD) d 7.42e7.27 (m, 5H), 3.40e3.23
(m, 2H), 2.99 (dd, J¼ 14.8, 7.5 Hz, 1H), 2.46e2.33 (m, 1H); 13C NMR
(CD3OD) d 131.99 (s), 128.26 (s, 2C), 127.78 (s, 2C), 127.28 (s), 112.80
(t, J¼ 288.0 Hz), 36.69 (d, J¼ 5.9 Hz), 32.00 (t, J¼ 11.0 Hz), 25.63 (t,
J¼ 10.7 Hz); HRMS (ESI) calculated for C10H12F2N ([MþH]þ): m/z
184.0932; found: 184.0914.
4.19. Calcium flux assay
Calcium flux assay were performed with Flp-In-293 cells stably
expressing the human 5-HT2A, 5-HT2B, or 5-HT2CeINI using a
FLIPRTETRA fluorescence imaging plate reader (Molecular Dynamics)
as previously described [17,24]. Briefly, cells were seeded in 384-
well poly-L-lysine plates at a density of 10,000 cells/well in 1%
dialyzed FBS DMEM containing 1 mg/mL tetracycline for inducible
expression. Next day, the medium was decanted, and cells were
loaded with Fluo-4 Direct dye (Invitrogen, 20 mL/well) for 1 h at
37 C in drug buffer (1HBSS, 2.5mM probenecid, and 20mM
HEPES, pH 7.4). Drug dilutions were prepared at 5 finalconcentration in drug buffer (1HBSS, 20mM HEPES, 0.1% BSA,
0.01% ascorbic acid, pH 7.4). Plates were loaded into the FLIPR, a 10 s
baselinewas acquired, 5 mL per well of drugwas added, and calcium
flux was measured (1 read/s) for 300 s. Fluorescence in each well
was normalized to the average of the first 10 reads (i.e., baseline
fluorescence), then the maximum-fold increase and fold-over-
baseline were acquired and plotted as a function of drug concen-
tration. Data were normalized to % 5-HT stimulation and analyzed
using log(agonist) vs. response in Graphpad Prism 5.0.
4.20. Docking simulation
The three-dimensional (3D) structures of 8 and 21c were built
up in their protonated forms and energy-minimized by molecular
mechanics using ChemBio3D 12.0 (MM2). The crystallographic
structure of 5-HT2C-active was obtained from the Protein Data Bank
(PDB) with the access code 6BQG (resolution of 3 Å). All docking
simulations were conducted in the binding pocket of 5-HT2C-active
by using GOLD 5.4 software (CCDC Software Limited). GOLD 5.4 has
four fitness functions available: GoldScore, ChemScore, ASP, and
ChemPLP. All fitness functions were evaluated by re-docking of the
co-crystallized ligands of each crystallographic complex to identify
the most suitable fitness function for the docking into 5-HT2C-active.
Crystallographic waters were removed during docking. Hydrogen
atoms were added to the protein according to the data inferred by
the program on the ionization and tautomeric states. The set of
amino acid residues selected as the binding site was determined
within a 6 Å radius from each co-crystallized ligand. After re-
docking, the root-mean-square deviation (RMSD) between the
best result for each fitness function, and the experimental confor-
mation of ERG were calculated. The fitness function with the lower
value of RMSD (no more than 2.0 Å), and the best performance in
the re-docking was used for the docking of 8 and 21c. The Gold-
Score was the best fitness function found for both structures
(higher RMSD obtained equal to 1.15 Å). The program optimizes
hydrogen-bond geometries by rotating hydroxyl and amino groups
of the amino acid side chains. The score of each pose identified is
calculated as the negative of the sum of a series of energy terms
involved in the protein-ligand interaction process, so higher posi-
tive score values means better interactions. The figures of the best
docking poses for each compound were generated using PyMOL
(Schr€odinger, LLC).
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